labstyle innovations corp (DRIO) Key Developments
LabStyle Innovations Corp. Appoints Todd Durniak as Senior Vice President and General Manager for US
Jul 1 15
LabStyle Innovations Corp. announced the appointment of Todd Durniak as Senior Vice President and General Manager for the U.S. Durniak brings to the company over 20 years of medical device commercial and technical leadership, most recently as the Vice President and General Manager of Neighborhood Diabetes.
LabStyle Innovations Corp. Launches Dario Diabetes Management Solution in Canada
Jun 25 15
LabStyle Innovations Corp. announced the Dario is now available for sale in Canada. The compact all-in-one system that helps people with diabetes monitor blood sugar levels and proactively manage their disease using their smartphone or tablet, is distributed by Auto Control Medical. Now available through www.mydario.ca, Dario's suggested retail price is $39.95 and it will be available at selected pharmacies including London Drugs. Dario connects via a headphone jack to turn a mobile device into a glucose monitor, and comes equipped with a lancing device and test strips to take blood samples on the spot. It provides the diabetes patient's real-time and historical blood glucose data to spot patterns, recommend treatments and support behavior changes. Its web interface also makes it easy to get upgrades and share health information with healthcare providers and loved ones.
LabStyle Innovations Corp. Approves Amendments to the Certificate of Incorporation
Jun 16 15
LabStyle Innovations Corp. announced that at the AGM held on June 15, 2015, it has approved certificate of amendment to the company's certificate of incorporation with the Delaware Secretary of State increasing the number of authorized shares of the company's common stock, par value $0.0001 per share from 80,000,000 to 160,000,000.
LabStyle Innovations Corp. Announces Partnership with Maccabi Healthcare
May 26 15
LabStyle Innovations Corp. (DRIO) announced that in partnership with Maccabi Healthcare, it has launched the comprehensive Dario Diabetes Management Solution as part of Maccabi's advanced Telecare unit (MOMA). The Dario is a proprietary customized diabetes management solution that enables remote treatment for diabetes aiming to improve overall outcomes for patients. Maccabi has integrated the Dario(TM) into MOMA, leveraging LabStyle's cutting edge online and mobile healthcare technologies. Through MOMA, Maccabi is now providing chronic diabetes patients a service of advanced multi-disciplinary support and care through a national call center in coordination with the client's primary physician and other community-based resources. Each MOMA member with diabetes is receiving their own Dario(TM) smart meter for managing and monitoring their diabetes. Caretakers at call centers now have a direct online view and proactive communication over the Dario(TM) mobile platform.
LabStyle Innovations Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015
May 15 15
LabStyle Innovations Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenues of USD 0.067 million. Operating loss was USD 1.777 million compared to USD 2.668 million a year ago. Net loss was USD 1.638 million compared to USD 2.984 million a year ago. Basic and diluted loss per share was USD 0.08 compared to USD 0.70 a year ago. Net cash used in operating activities was USD 1.525 million compared to USD 2.337 million a year ago. Purchase of property and equipment was USD 0.036 million compared to USD 0.116 million a year ago. Non-GAAP adjusted LBITDA was USD 1.573 million for the first quarter of 2015, compared to approximately USD 1.961 million Non-GAAP adjusted LBITDA for the first quarter of 2014. Basic and diluted Non-GAAP adjusted LBITDA per share was USD 0.07 compared to USD 0.46 a year ago.